Westlake Omics

Westlake Omics is a Hangzhou-based biotech company founded in July 2020 that applies AI to proteomics big data for clinical diagnosis and drug development . It builds on mass spectrometry-based multi-omics technology to discover quantifiable biological patterns, with a focus on precision medicine applications including tumor diagnostics . The company raised tens of millions of RMB in seed funding in early 2021, with Gaorong Ventures as a co-lead investor, followed by hundreds of millions of RMB in a Pre-A round in January 2022 led by Efung Capital and Hillhouse Venture Capital, with Gaorong also participating . Founder Guo Tiannan has described the company's mission as using AI-powered proteomics to solve problems across disease diagnosis and AI-driven pharmaceutical research . In late 2022, Westlake Omics launched a spatial proteomics product line aimed at mapping protein expression patterns in tissue samples .